NIH grant to study prenatal ultrasound and birth defects
As the result of a new National Institutes of Health grant, a collaboration is under way between the School of Public Health and the Medical School to study the usefulness and accuracy of prenatal ultrasound examinations.
Dr. Kim Waller, associate professor of epidemiology, School of Public Health, has received a $370,000 Exploratory/Developmental Grant (R21) from the National Institute of Child Health and Human Development to conduct the study, and Dr. Michael Lucas, professor of obstetrics and gynecology, will serve as a co-investigator on the grant, contributing expertise on the interpretation of prenatal ultrasound exams.
This study will assess the accuracy of approximately 76,000 prenatal ultrasounds performed between 13 and 28 weeks of gestation to detect approximately 38 different structural malformations of the fetus. Information from this study will be of immediate use to physicians and pregnant women, assisting them in making informed choices concerning the usefulness of routine prenatal ultrasound examinations to detect birth defects.
“Only 60 to 70 percent of pregnant women in the United States receive prenatal ultrasounds,” Waller said. “Common reasons for performing an ultrasound exam are to check the gestational age of the fetus or to assess vaginal bleeding. Previous studies have shown that prenatal ultrasound exams can fail to detect many birth defects. In addition, questions have been raised about the usefulness of detecting birth defects prior to delivery. We hope to address both of these issues in our study,” Waller said.
The two-year study will include a multi-ethnic cohort of approximately 76,000 women who had prenatal ultrasound exams given in UT ob/gyn clinics between 1998 and 2006. The study will include a review of an estimated 1,450 infants with structural malformations and will be one of the most statistically powerful studies of the ability of prenatal ultrasound to detect congenital anomalies.
“This will be one of the largest studies in the United States, as most of the previous studies of this kind have been conducted in Europe,” Waller added.
-D. Brown
For more Headlines, see Page 2 Stories
Callies named development director
Jackie Callies is the new executive director of development and alumni relations for the Medical School.
“I am very pleased to have Jackie on board to lead our fund-raising efforts, knowing that philanthropy is an area we must concentrate on to ensure the future success of the Medical School,” said Dean Giuseppe Colasurdo.
Callies, a native Galvestonian, comes to the Medical School from The University of Texas Medical Branch, where she was director of development and had responsibilities for major gifts in that institution’s $250 million campaign, which finished above goal and ahead of schedule.
“I am grateful to have had the opportunity to help them with that campaign, starting with the feasibility study. We finished it 18 months sooner than expected,” she said, adding that she worked at UTMB for more than 12 years.
Callies said she is looking forward to bringing that type of fund-raising success to the Medical School.
“There is a great story to tell here and an enormous amount of opportunities,” she said. “I’m excited to be coming in at this time to bring them to light throughout the state and the country – we’ve been in the shadows too long.”
Among her goals, Callies said, is to engage the alumni as volunteers and donors.
“I’m also looking forward to working with and learning from Dr. Colasurdo. He has a well defined vision and tremendous energy, and I want to help him build upon the school’s strengths,” she added.
Callies is relocating to League City with her husband and two sons, ages 12 and 6.
-D. Brown
For more Headlines, see Page 2 Stories
Cardiologists Celebrate 30 Years of Advances in Coronary Angioplasty
Three decades ago, critics were calling coronary angioplasty a recipe for disaster. The notion that an inflated, miniature balloon at the end of a catheter could conquer heart disease was, to many, preposterous.
Dr. Andreas Roland Gruentzig didn’t let the skeptics dissuade him. He doodled designs on cocktail napkins, cooked up balloons and catheters in his kitchen and worked in laboratories to refine the instruments that would eventually allow heart patients the option of undergoing a knifeless procedure to push aside blockages in their coronary arteries.
On Sept. 16, 1977, Gruentzig performed the first angioplasty in a human heart – opening a choked artery in the heart of an insurance salesman and revolutionizing the treatment of coronary artery disease. With this procedure came a brand-new specialty called interventional cardiology
Thirty years later, physicians at the Medical School are celebrating the anniversary of angioplasty and the advancements they have helped bring to the field since the early days of interventional cardiology.
|
Dr. H. Vernon "Skip" Anderson |
Dr. Richard W. Smalling and Dr. H. Vernon “Skip” Anderson, both professors in the Department of Internal Medicine’s Division of Cardiology, traveled to Zurich, Switzerland, to participate in an international coronary angioplasty conference last week, where Gruentzig initiated a new era in the treatment of heart disease. The two Houston cardiologists, who treat patients in the cardiac catheterization laboratories at Memorial Hermann Heart & Vascular Institute – Texas Medical Center, are among only four physicians from Texas invited to give lectures at the international event.
Smalling gave a history lesson on debulking – a method by which artherectomy is used to remove large amounts of plaque. Anderson presented a lecture on the role of evidence gathering and its relevance to the advancement of treatments for coronary artery disease.
Their reflections will be used in materials that will be presented Sept. 28 at the inauguration of the Andreas Gruentzig Exhibit at the American College of Cardiology Heart House in Washington, D.C.
Smalling and Anderson were both still in medical training when Gruentzig performed the first angioplasty. There were no textbooks on interventional cardiology. There was just Gruentzig, his data and his teachings, along with a few satisfied patients who were thrilled they had escaped open-heart surgery for a kinder, gentler solution to their chest pain.
Gruentzig’s medical milestone in 1977 didn’t make an immediate impression on either Smalling or Anderson, but today they agree his achievement ultimately shaped their careers as cardiologists.
Smalling said he was initially leery. “The technique was very crude. There was no way to really guide the balloon, and you just had to hope it went in the right place,” recalled Smalling, holder of the Jay Brent Sterling Professorship in Cardiovascular Medicine at the UT Medical School at Houston. “I held back a little bit.”
In the spring of 1982, Smalling decided to participate in one of Gruentzig’s demonstration courses in Atlanta – mainly because he felt angioplasty was a promising therapy for blockages in peripheral blood vessels. After that, he was convinced it was a viable alternative to open-heart surgery. He arranged to buy all the equipment that would be needed to offer coronary angioplasty in Houston. In June 1982, he performed the first angioplasty at Memorial Hermann. The 42-year-old male patient with a single blockage made a full recovery.
“By 1982, it was an approved procedure, but few cardiologists were offering it,” said Smalling, director of interventional cardiovascular medicine at Memorial Hermann. “In that first year, we didn’t do too many angioplasties. We had a group. I think we called it the Angioplasty Society, and we met with cardiologists from some of the other hospitals to review cases. Some were doing elective cases. At Hermann, most of ours were heart attack patients.”
Times have certainly changed. Approximately 1,500 coronary angioplasties and 1,000 peripheral angioplasties are performed annually at Memorial Hermann. And Smalling and Anderson, along with fellow interventionalists and physicians in the Department of Emergency Medicine, lead an initiative to quickly get heart attack patients into the Cath Lab for treatment to prevent catastrophic heart damage and death.
Anderson had the opportunity to train with Gruentzig as one of his research fellows at Emory University. Anderson was a believer, but he remembers the skepticism of others. “There was a belief that putting something inside the vessel would create more harm than good,” Anderson said. “So in those first years, it was a priority to come up with enough data to prove that it could be done safely.”
Other techniques -- with names such as crackers, breakers, stretchers, drillers, scrapers, shavers, and burners – came and went, but the angioplasty balloon always remained. “It is proven and valuable, and it continues to evolve,” Anderson said. “We’ve been able to help quite a few patients because of it.”
In 30 years, cardiac imaging and catheterization equipment, as well as the training, has improved remarkably, Anderson said. He added that one of the most significant advances has been the development of the stent, which is designed to keep the artery open after the balloon has cleared the blockage. “Now we have drug-coated stents to help heal the inside of the artery,” Anderson said. “As our understanding of pharmacology grows and the equipment improves, these stents will continue to get better and better.”
Anderson, Smalling and their colleagues at the Medical School continue to be at the forefront of research that is advancing interventional procedures for their patients. Their clinical trials have helped improve techniques and devices used to clear blockages in coronary arteries and carotid arteries, repair heart defects and stop a heart attack before it causes irreparable damage. Currently, some of their studies related to angioplasty include the use of stem cells, the timing of treatment and adjunctive pharmacology.
“Just as we are doing now, the founder of angioplasty was himself driven to collect and analyze data,” Anderson said. “He was driven by an unbelievable desire to show this was safe. That passion – that same drive – continues. We want to provide the safest, most effective treatments for our patients.”
-M. Raine
For more Headlines, see Page 2 Stories
|
